KDR and neoplasm: Apatinib, a selective VEGFR‐2 tyrosine kinase inhibitor used for advanced GC therapy, has been reported to induce intratumor hypoxia.[5, 9] Therefore, we treated the subcutaneous tumor model with 120 mg kg−1 apatinib (oral gavage, daily), followed by a significant reduction in tumor angiogenesis (Figure 1C).